Project/Area Number |
23659088
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Sojo University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
MARUYAMA Toru 熊本大学, 薬学部, 教授 (90423657)
WATANABE Hiroshi 熊本大学, 薬学部, 准教授 (70398220)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | アルブミン / 血液浄化法 / 分子進化工学 / 毒素中和 / ハイブリッド / 毒性中和 |
Research Abstract |
This study was undertaken to design and evaluate recombinant albumin mutant( specially, domain II mutant)with high bilirubin (BR) binding affinity via phage display technology.The results obtained here identified the amino acid residues that interact carboxylatesof BR in HSA, and also produces HSA domain II mutants with high BR binding affinity. To our knowledge, this is the first finding on HSA mutant with enhanced binding affinity to BR. This approach could be applied to other HSA bound toxic compounds that responsible for the progression oifseadse and thereby it will pave the way for the development ofminimally invasive and low cost blood clarification method.
|